Chr. Hansen enters first collaboration on production of a next generation probiotic from the Human Microbiome

Chr. Hansen enters first collaboration on production of a next generation probiotic from the Human Microbiome
Press Release | Jan 14. 2016 07:08 GMT

Bacteria that live in and on our bodies outnumber the number of human cells by 10 to 1. There is an increased awareness that these bacteria, called the microbiome, play a crucial role in human health and diseases. Numerous studies have highlighted the therapeutic potential of specific bacteria in preventing and treating metabolic, gastrointestinal and other diseases. Today, Chr. Hansen and Caelus Health announce their collaboration on the development of Eubacterium hallii as a next generation probiotic for prevention and treatment of metabolic disease.

Recent studies have demonstrated the involvement of the intestinal microbiota in insulin resistance. Caelus Health have identified and patented a single species, E. hallii, which through preclinical studies has proven to be capable of reducing insulin resistance, a primary symptom of type 2 diabetes. Caelus’ lead strain, CP-001, is a formulation of E. hallii and is currently in phase I clinical study.

The objective of the collaboration between Chr. Hansen and Caelus Health is to develop a CP-001 product formulation that will allow for progression to a phase II clinical trial and a subsequent market introduction. As part of this collaboration, Chr. Hansen will develop a production process and pilot material for clinical trials which Caelus Health will run to explore the use of Eubacterium hallii for prevention and treatment of metabolic disease

First of several projects within the Human Microbiome space

Johan van Hylckama Vlieg PhD, Senior Director, Microbiome, Chr. Hansen, says: “Chr. Hansen has unparalleled expertise in fermentation and food and pharma grade production of bacteria. The collaboration with Caelus is in full alignment with our strategy to become the partner of choice for companies wanting to develop new generations of probiotic products and therapeutic microbes. The agreement with Caelus is an important milestone as the first of several projects within the Human Microbiome space for Chr. Hansen”

Luc Sterkman MD, CEO, Caelus states: “We are very pleased to announce this cooperation and are confident that Chr. Hansen has all the expertise and capabilities to develop an advanced formulation of CP-001, which we will further study in upcoming phase 2 clinical studies. This E. hallii based product is the first of a series of Microbiome-based products, which Caelus plans to bring to the market.”

For more information please contact:

Chr. Hansen: Klara Halkjaer,
+45 53 39 23 62

Cealus Health: LGW Sterkman


Caelus Health is an Amsterdam-based biotech company. Caelus is dedicated to the commercialisation of functional food and pharmaceutical products for the prevention and early treatment of cardio-metabolic diseases. Based on the strong correlation between the intestinal microbiome and health, the company is developing an entirely new class of microbiota-based therapeutics for the reduction of insulin resistance and prevention of Type 2 Diabetes Mellitus (T2DM) in people with metabolic syndrome (MetS). The first product is now in clinical phase of development and is based on Eubacterium hallii. Life Sciences Fund Amsterdam (LSFA) is the founding investor.

科汉森是为食品、营养、制药和农业行业开发天然解决方案的一家全球领先的生物科学公司。我们为各种食品、糖果、饮料、膳食补充剂、动物饲料和植物保护开发和生产发酵剂、酶、益生菌和天然色素。我们的产品创新基于大约 40,000 株微生物菌株——我们喜欢称之为“有益菌群”。我们的解决方案帮助食品制造商实现以更少的资源生产更多的产品,同时也减少了化学添加剂和其他合成物添加剂的使用,这使得我们的产品与当今世界息息相关。可持续性是科汉森改善食物和健康的愿景不可分割的一部分。2019 年,科汉森被 Corporate Knights 评为全球最可持续发展的公司,这要归功于我们为可持续发展付出的巨大努力以及我们与客户建立的众多合作伙伴关系。145 年来,我们一直在不断地为我们的合作伙伴以及全球终端消费者创造价值。令我们感到自豪的是,每天有超过 10 亿人在消费含有我们天然成分的产品。科汉森成立于 1874 年,并已在哥本哈根证券交易所上市。